Srpski arhiv za celokupno lekarstvo 2015 Volume 143, Issue 9-10, Pages: 578-583
https://doi.org/10.2298/SARH1510578S
Full text ( 213 KB)
Levels of vascular endothelial growth factor during first six months of peritoneal dialysis
Stojimirović Biljana (School of Medicine, Belgrade + Clinical Center of Serbia, Clinic of Nephrology, Belgrade)
Jovanović Nataša (School of Medicine, Belgrade + Clinical Center of Serbia, Clinic of Nephrology, Belgrade)
Trbojević-Stanković Jasna (School of Medicine, Belgrade + Clinical-Hospital Center “Dr Dragiša Mišović”, Department of Dialysis, Belgrade)
Krstić Slobodan (University of Belgrade, School of Medicine, Belgrade + Clinical Center of Serbia, Clinic for Digestive Diseases, Belgrade)
Nešić Dejan (School of Medicine, Institute of Medical Physiology, Belgrade)
Žunić-Božinovski Snežana (School of Medicine, Institute of Pathophysiology, Belgrade)
Introduction. Chronic peritoneal dialysis (PD) up-regulates vascular
endothelial growth factor (VEGF) synthesis and VEGF is found in drained
dialysate (dd). Objective. Aims of this prospective study were to evaluate
serum (s) and ddVEGF concentration during the first six months of PD,
relationships between these concentrations and demographic and biochemical
parameters, presence of diabetes, peritonitis, and the use of medications.
Methods. The study included 20 patients, with the mean age of 62.9±12.69, 11
of whom were affected by diabetes mellitus. Fasting venous blood samples were
taken at the beginning and after six months of PD, in tri-potassium
ethylenediaminetetraacetic acid (K3EDTA) vacutainer. Results. After six
months of PD, sVEGF concentrations increased significantly, without
significant change in ddVEGF. Concentrations of sVEGF at the beginning of
chronic PD treatment directly significantly correlated with serum fibrinogen,
and after six months with fibrinogen and glycemia. In patients receiving
erythropoiesis-stimulating agent (ESA), levels of sVEGF and ddVEGF were lower
at baseline, while after six months of PD ddVEGF increased. In patients not
receiving ESA, sVEGF increased more prominently, while ddVEGF decreased. The
changes were not statistically significant. Patients receiving
angiotensinconverting- enzyme inhibitor (ACEi) had sVEGF and ddVEGF levels
insignificantly lower than those not using ACEi, however sVEGF significantly
increased during six months of PD. After six months of PD, ddVEGF was
significantly higher compared to those not using ACEi. Treatment with statins
did not significantly influence levels of sVEGF and ddVEGF during the
follow-up. Concentrations of sVEGF were continually lower than those of
ddVEGF and increased more, while concentrations of ddVEGF were higher in
patients using statins. Conclusion. Serum and drained dialysate
concentrations of VEGF in PD patients were connected with poorer metabolic
profile, while the role of inflammation and treatment agents should be
studied further.
Keywords: peritoneal dialysis, VEGF, statins, erythropoietin stimulating agents, angiotensin converting enzyme inhibitors